

1 **Myeloid Cell Glucocorticoid, Not Mineralocorticoid Receptor Signaling, Contributes to**
2 **Salt-Sensitive Hypertension in Humans via Cortisol**

3 Claude F. Albritton^{1,2#}, Mert Demirci^{3#}, Kit Neikirk⁴, Lale A. Ertuglu³, Jeanne A Ishimwe¹, Ashley
4 L Mutchler¹, Quanhu Sheng⁵, Cheryl L Laffer¹, Celestine N. Wanjalla¹, Taseer Ahmed^{1,6},
5 Alexandria Porcia Haynes¹, Mohammad Saleem¹, Heather K. Beasley⁴, Andrea G. Marshall⁴, Zer
6 Vue⁴, Alp T Ikizler³, Thomas R. Kleyman⁷, Valentina Kon⁸, Antenor Hinton⁴, and Annet
7 Kirabo^{1,4,9,10,11*}

8

9 ¹Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical
10 Center, Nashville, TN 37212-8802, USA.

11 ² Department of Biomedical Sciences, School of Graduate Studies, Meharry Medical College,
12 Nashville, TN 37208-3501, USA.

13 ³Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University
14 Medical Center, Nashville, TN, United States

15 ⁴Department of Molecular Physiology & Biophysics, Vanderbilt University, Nashville, TN
16 37212-8802, USA.

17 ⁵Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37212-8802,
18 USA.

19 ⁶Department of Pharmacology, College of Pharmacy, University of Sargodha, University Road,
20 Sargodha, Punjab, 40100, Pakistan

21 ⁷Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
22 15260, USA.

23 ⁸Division of Nephrology, Department of Pediatrics, Vanderbilt University Medical Center,
24 Nashville, TN.

25 ⁹Vanderbilt Center for Immunobiology

26 ¹⁰Vanderbilt Institute for Infection, Immunology and Inflammation

27 ¹¹Vanderbilt Institute for Global Health

28 Short title: Myeloid Glucocorticoid-Cortisol in Salt Sensitivity

29 #Contributed equally

30

31

32 *Corresponding author:

33 **Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A**

34 Division of Clinical Pharmacology, Department of Medicine,

35 Vanderbilt University Medical Center,

36 Email: annet.kirabo@vumc.org

37

38

39 **ABSTRACT**

40 **BACKGROUND:** Salt sensitivity of blood pressure (SSBP) is an independent risk factor for
41 cardiovascular morbidity and mortality, yet the etiology is poorly understood. We previously
42 found that serum/glucocorticoid-regulated kinase 1 (SGK1) and epoxyeicosatrienoic acids (EETs)
43 regulate epithelial sodium channel (ENaC)-dependent sodium entry into monocyte-derived
44 antigen-presenting cells (APCs) and activation of NADPH oxidase, leading to the formation of
45 isolevuglandins (IsoLGs) in SSBP. Whereas aldosterone via the mineralocorticoid receptor (MR)
46 activates SGK1 leading to hypertension, our past findings indicate that levels of plasma
47 aldosterone do not correlate with SSBP, and there is little to no MR expression in APCs. Thus, we
48 hypothesized that cortisol acting via the glucocorticoid receptor (GR), not the MR in APCs
49 mediates SGK1 actions to induce SSBP.

50 **METHODS:** We performed cellular indexing of transcriptomes and epitopes by sequencing
51 (CITE-Seq) analysis on peripheral blood mononuclear cells of humans rigorously phenotyped for
52 SSBP using an inpatient salt loading/depletion protocol to determine expression of MR, GR, and
53 SGK1 in immune cells. In additional experiments, we performed bulk transcriptomic analysis on
54 isolated human monocytes following *in vitro* treatment with high salt from a separate cohort. We
55 then measured urine and plasma cortisol, cortisone, renin, and aldosterone. Subsequently, we
56 measured the association of these hormones with changes in systolic, diastolic, mean arterial
57 pressure and pulse pressure as well as immune cell activation via IsoLG formation.

58 **RESULTS:** We found that myeloid APCs predominantly express the GR and SGK1 with no
59 expression of the MR. Expression of the GR in APCs increased after salt loading and decreased
60 with salt depletion in salt-sensitive but not salt-resistant people and was associated with increased
61 expression of *SGK1*. Moreover, we found that plasma and urine cortisol/cortisone but not

62 aldosterone/renin correlated with SSBP and APCs activation via IsoLGs. We also found that
63 cortisol negatively correlates with EETs.

64

65 **CONCLUSION:** Our findings suggest that renal cortisol signaling via the GR but not the MR in
66 APCs contributes to SSBP via cortisol. Urine and plasma cortisol may provide an important
67 currently unavailable feasible diagnostic tool for SSBP. Moreover, cortisol-GR-SGK1-ENaC
68 signaling pathway may provide treatment options for SSBP.

69

70

71 **Keywords:** Salt-sensitive hypertension, cortisol, glucocorticoid, antigen-presenting cells,
72 monocytes

73 **Introduction:**

74 Globally, dietary salt consumption has increased with the evolution of processed foods, leading to
75 a greater risk of hypertension and cardiovascular disease.^{1–3} Salt sensitivity of blood pressure
76 (SSBP) refers to the heterogeneity in blood pressure responses according to dietary salt intake.¹
77 Individuals who respond to high dietary salt intake with a greater blood pressure increase in an
78 acute manner are classified as salt-sensitive (SS)—a condition that has commonly been linked to
79 genetic abnormalities⁴—and face a higher risk of cardiovascular events and deaths due to excessive
80 salt intake compared to salt-resistant (SR) individuals.^{1–5} The etiology of SSBP is not clearly
81 understood, yet mechanistic investigation is hampered by the absence of feasible diagnostic
82 screening tools.

83

84 Isolevuglandins (IsoLGs) are highly reactive products of lipid oxidation that form covalent bonds
85 with lysine residues, leading to post-translational protein modifications.⁶ We found that IsoLGs
86 accumulate and act as neoantigens in antigen-presenting cells (APCs) to activate T cells and
87 promote hypertension.^{7,8} Our studies indicate that dietary sodium (Na⁺) is a potent stimulus for
88 IsoLG-adduct formation in APCs via activation of the NADPH oxidase.⁹ Mice lacking NADPH
89 oxidase do not form IsoLG adducts, and pharmacological scavenging of IsoLGs prevents dendritic
90 cell (DC) activation, hypertension, and end-organ damage.^{6,9} Thus, therapeutic strategies to reduce
91 Na⁺ intake or signaling may reduce inflammation and hypertension.¹⁰

92

93 The epithelial sodium channel (ENaC), which is implicated in the pathogenesis of SSBP^{11–13}, has
94 been studied extensively in the kidney, where it regulates electrolyte and volume balance. Our
95 studies indicate that dendritic cell (DC) entry of extracellular Na⁺ requires ENaC, which is then
96 exchanged for Ca²⁺ via the Na⁺/Ca²⁺ exchanger with the resultant activation of protein kinase C
97 (PKC). PKC phosphorylates the p47 subunit of NADPH oxidase leading to formation of
98 superoxide and downstream immunogenic IsoLG-adducts in APCs.⁶ These APCs activate T cells
99 and inflammatory cytokines which induce vascular and renal Na⁺ transporter dysfunction and
100 increase in blood pressure.⁸ We found that the expression of ENaC in APCs in response to high
101 salt is regulated by both epoxyeicosatrienoic acids (EETs) and serum/glucocorticoid regulated
102 kinase 1 (SGK1).¹⁴ Moreover, we found that SGK1 plays a role in SSBP as its expression in APCs

103 parallel blood pressure changes during salt loading/depletion in SS people.¹⁵ However, the
104 upstream signaling mechanisms leading to the expression of APC SGK1 in SSBP are unknown.
105
106 Medical conditions that result in excessive cortisol have been associated with hypertension and are
107 associated with defects in 11 β -hydroxysteroid dehydrogenases (11 β -HSDs)¹⁶. Impairment in 11 β -
108 HSD increases cortisol in peripheral tissues, further exacerbated by high salt intake.¹⁶⁻¹⁸ Excess
109 cortisol and 11-deoxycortisol, as well as elevated cortisol-to-cortisone ratios, have been implicated
110 in hypertension¹⁹. Although aldosterone typically binds to the mineralocorticoid receptor (MR) to
111 increase membrane expression of ENaC via SGK1²⁰, cortisol also binds to MR under similar
112 conditions^{21,22}. It subsequently induces SGK1 expression in human epithelial cells by activating
113 glucocorticoid response elements.²³ There is a strong correlation between high-salt intake, SSBP,
114 and mutations in the glucocorticoid receptor (GR) gene *NR3C1*, whose product regulates many
115 mammalian genes, such as those for inflammatory cytokines^{24,25}. However, the upstream
116 mechanisms regulating SGK1-ENaC activation in APCs leading to SSBP are not known. Here, we
117 characterized the role of cortisol and the APC GR-dependent regulatory role of SGK1 in SSBP.
118

119 METHODS

120 Human Studies

121 Following approval from the Institutional Review Board of Vanderbilt University Medical Center
122 for all experimental procedures, we adhered strictly to the principles outlined in the Declaration of
123 Helsinki and required written consent prior to enrollment. We studied two cohorts described
124 previously^{7,8}.

125

126 **Phenotyping of SSBP: Salt-Loading and Salt-Depletion Protocol:**

127 **-Study Population**

128 In cohort 1, twenty-five hypertensive participants ages 18–65, with systolic blood pressure (SBP)
129 >130 mmHg or diastolic blood pressure (DBP) >80 mmHg were recruited at Vanderbilt University
130 Medical Center (VUMC) from 2019–2023. In cohort 2, we conducted RNA sequencing on human
131 monocytes after high-salt treatment *in vitro*. The monocytes were isolated from eleven healthy
132 women aged between 22-46 years. Individuals were excluded for 1) renovascular or endocrine
133 causes of secondary hypertension, 2) infectious or inflammatory disease (i.e., active infection or

134 connective tissue disorder), 3) a history of an acute cardiovascular event within six months of the
135 study, 4) treatment-induced high blood pressure or (e.g., selective serotonin reuptake inhibitors
136 and serotonin and norepinephrine reuptake inhibitors, chronic use of decongestants or non-
137 steroidal anti-inflammatory drugs), 5) treatments that alter the immune response (e.g.,
138 immunomodulators, immunosuppressants, glucocorticoids), or 6) pregnancy. Demographic and
139 clinical data were collected from the participants and their clinical charts. A physical exam and
140 blood pressure measurements using an automated Omron HEM-907XL monitor were obtained
141 during the screening visit. Plasma and urine EETs were measured via liquid chromatography-mass
142 spectrometry.

143

144 **-Study Protocol**

145 Antihypertensive medications were discontinued two weeks before the study visit for those on
146 antihypertensive treatment. Subjects were instructed to maintain their usual diet and activity level
147 during this period. To ensure the safety of participants who stopped taking their medications, we
148 instructed patients to check their blood pressure twice a day, while seated, after resting for 5
149 minutes, and to inform the study physician of the results. One day before admission, subjects were
150 instructed to collect a 24-hour baseline urine sample. Participants were admitted to the VUMC
151 Clinical Research Center for three nights to assess salt sensitivity using an inpatient salt loading
152 and depletion protocol, as described previously in detail²⁶. The participants were continuously
153 monitored by the study physician. A normal dinner was provided to the participants on admission
154 day. An ambulatory blood pressure monitor (Spacelabs 90207) was placed on the participants the
155 next morning. Baseline blood samples were drawn at 8 AM before any intervention. Salt loading
156 (on day 1) was achieved with a diet containing 160 mEq NaCl (prepared by the University of
157 Alabama Bionutrition Core of the Clinical Research Unit Metabolic Kitchen) and with a 2 L
158 intravenous infusion of normal saline, administered from 8 AM to 12 PM. A 24-hour urine sample
159 was collected from 8 AM on day 1 to 8 AM on day 2. Participants were advised to retire at 10 PM
160 each day. The effects of salt depletion were measured on day 2. Blood samples were collected at
161 8 AM after overnight fasting to measure salt loading. Salt was depleted using three 40-mg doses
162 of oral furosemide administration at 8 AM, 12 PM, and 4 PM and a low-salt diet containing 10
163 mEq NaCl. Two 12-hour urine samples were collected from 8 AM to 8 PM to measure the effects
164 of furosemide and from 8 PM on day 2 to 8 AM on day 3 to measure salt depletion. The third

165 blood sample was drawn at 8 AM on day 3 to measure salt depletion. The participants were
166 discharged following blood and urine collection. BP and pulse rate were recorded every 15 minutes
167 from 6 AM to 10 PM and every 30 minutes at night throughout the three study days. The average
168 of the blood pressure recordings from 6 AM to 8 AM on day 1 was used as baseline blood pressure.
169 The blood pressures recorded between 12 PM and 10 PM on days 1 and 2 were used to calculate
170 the average blood pressures during salt loading and depletion, respectively. No specific threshold
171 was used to define SS or SR, but rather, salt sensitivity was analyzed as a continuous variable.
172

173 Throughout the study, participants had unlimited access to water; however, their food intake was
174 limited to the diet provided according to the protocol. Before interventions, body weight was
175 recorded at baseline and daily at 7 AM. Body mass index (BMI) was calculated as weight in
176 kilograms divided by height in square meters.
177
178

179 **Laboratory Analysis**

180 Laboratory data including electrolytes and creatinine, plasma renin concentration, and aldosterone
181 were analyzed at the VUMC Pathology Laboratory. Plasma renin direct renin/renin mass and
182 plasma aldosterone were measured using chemiluminescent radioimmunoassay. Blood was
183 collected in EDTA tubes, centrifuged at room temperature, and separated immediately. Urine
184 specimens for four periods (24-hour baseline, 24-hour salt loading, 12-hour furosemide-induced
185 diuresis, and 12-hour salt depletion) were collected and refrigerated as described previously²⁷.
186

187 **Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq)**

188 As previously described⁸, we performed cell hashing and CITE-Seq analysis on PBMCs of nine
189 participants from cohort 1, depicted in Table 1 (Cohort1). Blood samples were collected at baseline
190 (day 1), after salt load (day 2), and salt depletion (day 3), as shown in Figure 1A. PBMCs from
191 each day were used for cell hashing and CITE-Seq analysis. Per the manufacturer's protocol
192 (Fisher Scientific, Cat# 14-959-51D), we used BD Vacutainer® CPT™ Mononuclear Cell
193 Preparation tubes to isolate PBMCs. We used antibody-oligonucleotide conjugates to stain the
194 isolated PBMCs and performed sample multiplexing with sample-specific hashtags. We
195 introduced the mixture of cells and an antibody-oligonucleotide complex into a microfluidic

196 system to capture the unique homing guide RNA (hgRNA) barcodes using custom beads
197 containing poly-dT and specific nucleotide sequences. The VANTAGE core generated small
198 vesicles containing a single bead and a single cell through oil inclusion, which encapsulated the
199 antibody-oligonucleotide complex. Then, the cell was lysed, followed by the synthesis of cDNA
200 and antibody-derived tags through reverse transcription.

201
202 We used 10x Genomics Cell Ranger 6.0.2 equipped with in-house scripts to quantify genes and
203 demultiplex sample-specific hashtags. The hashtag abundance cutoff for positive cells was
204 determined by the modified R package cutoff. Every cell was categorized as 1) a singlet with a
205 specific hashtag, 2) a doublet, or 3) negative. The genotypic results obtained from Souporcell were
206 combined with the results based on hashtags.²⁸ Subsequently, clustering analysis was performed
207 using Seurat²⁸ set to a resolution of 1.0. The cell type of each cluster was classified based on the
208 cell activity database^{29,30} and manually refined according to cell-specific marker genes. The
209 program edgeR³¹ was used to identify differential gene expression across conditions with absolute
210 fold change larger than 1.5 and FDR adjusted p value less than 0.05. The WebGestaltR³² package
211 was used for Genome Ontology and KEGG pathway over-representation analysis on differentially
212 expressed genes. GSEA³³ was used for gene enrichment analysis.

213
214 **Bulk RNA Sequencing and Bioinformatics**
215 As described previously,³⁴ we isolated peripheral blood mononuclear cells (PBMCs) from 40 mL
216 of heparinized blood from eleven healthy subjects and depicted in Table 1 (Cohort 2). Using a
217 Ficoll-gradient protocol, monocyte isolation kit (Miltenyi Biotec 130-091-151) was used to extract
218 monocytes via magnetic labeling and negative selection. Monocytes were cultured in 12-well
219 plates at a density of 1×10^6 /mL in Roswell Park Memorial Institute media 1640 (Gibco)
220 supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 1% HEPES, and 0.05 mM
221 2-mercaptoethanol with either 150 mM or 190 mM Na⁺. Bulk RNA sequencing of isolated
222 monocytes grown in a normal or high-salt medium *in vitro* was done by the Vanderbilt
223 Technologies for Advanced Genomics (VANTAGE) core to ensure a high RNA integrity number.
224 The VANTAGE core used an Illumina Tru-Seq RNA sample prep kit to perform polyadenylated
225 RNA sequencing, and paired-end sequencing was done on the Illumina HiSeq2500. FASTQ data
226 from the paired-end sequencing analysis were aligned against the human GRCh38 reference

227 genome assembly with TopHat 2 using the R package. The quaternary round of quality control for
228 raw data and alignment was conducted using QC3, and the MultiRankSeq method was used for
229 expression analysis. A false discovery rate (FDR < 0.05) was used to correct for multiple
230 hypothesis testing.

231
232 **Cortisol Analysis:** The metabolite contents of the urine and plasma samples from the 72-hour
233 protocol of cohort 1 (**Figure 1A, Table 1**) were extracted from the global untargeted metabolomic
234 analysis by Metabolon which uses ultra-high-performance liquid chromatography/tandem accurate
235 mass spectrometry. Raw data for each biochemical detected on a per-sample basis was expressed
236 as peak area (i.e., integrated area-under-the-curve), and these raw values were used in correlation
237 analysis.

238
239 **Statistical Analysis:** Statistical analysis was performed with Prism version 10.2 (GraphPad
240 Software, La Jolla, USA). Statistical significance was set to a p-value of 0.05. Correlation analyses
241 were performed to compare multiple interval or ratio variables. Associations of continuous
242 variables of interest were assessed with Spearman's rank correlation and Pearson's correlation test,
243 as specified in the respective figure legends. Trend lines and confidence intervals (CI) were
244 estimated by linear regression.

245

246 **RESULTS**

247 **The Glucocorticoid Receptor, but not the Mineralocorticoid Receptor is expressed in** 248 **Myeloid Antigen Presenting Cells**

249 To determine whether activation of APC SGK1 is downstream of the mineralocorticoid or the
250 glucocorticoid receptor, we performed single cell CITE-seq analysis on people assessed for SSBP
251 using a highly rigorous modified Weinberger protocol of salt-loading and salt-depletion in humans
252 illustrated in **Figure 1A** and as previously reported.^{3,5} **Table 1/Cohort 1** shows the demographics
253 of the study participants. As we have previously published, we found that the blood pressure
254 responses of participants to salt loading/depletion could be categorized into three main tertiles¹⁴.
255 Tertile 1 (blue) included the inversely salt-sensitive participants, Tertile 2 included the SR
256 participants, and Tertile 3 (red) included the most salt-sensitive participants. In contrast to these
257 very different changes in blood pressure, all subjects show virtually identical changes in 24-hour

258 urinary Na^+ excretion during salt loading and depletion. These results show that renal handling of
259 Na^+ is not different between SS and SR people and suggest a role for extra-renal mechanisms in
260 SSBP. As shown in **Figure 1B**, we found that while SGK1 and the GR (indicated by NR3C1) are
261 highly expressed in the APCs—including the monocytes and dendritic cells—there is little to no
262 expression of the MR (indicated by NR3C2) in these cells. **Figure 1B** shows the Uniform Manifold
263 Approximation and Projection (UMAP) to sub-clustered immune cell types, and how the
264 expression of NR3C1 and NR3C2 changes from baseline (D1) to salt-loading (D2) and salt-
265 depletion (D3) in SR and SS people. Accordingly, we found that changes in the expression of
266 SGK1 from salt loading to salt depletion correlated with changes in NR3C1 (**Figure 1C**). To
267 confirm these findings, we performed bulk RNA-sequencing on isolated monocytes from humans
268 treated with either normal-sodium (140 mM) or high-sodium concentrations (190 mM) in vitro.
269 As shown in **Figures 1B and 1D**, we found significant expression of NR3C1 and SGK1 but little
270 to no expression of NR3C2. Moreover, in accordance with our previous publication, immune cells
271 exhibited minimal to no expression of aldosterone synthase, encoded by CYP11B2, and both 11β -
272 HSDs, encoded by HSD11B1 and HSD11B2.³⁵ Since these enzymes are necessary for the
273 synthesis of aldosterone and the conversion of cortisol and cortisone, our results suggest that
274 aldosterone and cortisol are not synthesized in immune cells and point to an important role for the
275 glucocorticoid receptor in APC SGK1-ENaC activation in SSBP.

276

277 **Urine and Plasma Cortisol/Cortisone Correlate with Salt Sensitivity of Blood Pressure:**

278 To determine if cortisol plays a role in SSBP, we measured cortisol and its precursor cortisone in
279 the plasma and urine of people phenotyped for SSBP. We employed two delta variables in the
280 correlation analysis to investigate the effect of overall salt balance on blood pressure measures and
281 cortisol metabolism. Specifically, we analyzed the differences between salt loading and baseline
282 blood pressure measures, cortisol, and cortisone values to represent the effect of salt loading on
283 blood pressure and cortisol metabolism. Additionally, we included the difference between salt
284 loading and salt depletion to investigate the acute response to salt depletion. This approach allows
285 for a comprehensive analysis of the effects of salt balance on blood pressure and cortisol
286 metabolism. We found that changes in urine cortisol positively correlated with changes in SBP
287 and PP but not DBP or MAP (**Figure 2A**). We found no significant correlations between changes
288 in plasma cortisol with changes in SBP, DBP, MAP or PP (**Figure 2B**). Changes in urine cortisone

289 were not significantly correlated with changes in SBP, DBP, MAP or PP (**Figures 2C**). We found
290 a positive correlation between changes in plasma cortisone with changes in SBP and MAP but not
291 with DBP or PP (**Figure 2D**). These results suggest a role for urine and plasma levels of cortisol
292 and cortisone respectively in SSBP.

293

294 **Urine Cortisol Positively Correlates with Myeloid Cell activation via IsoLGs and negatively**
295 **associates with Epoxyeicosatrienoic Acids (EETs)**

296 To determine whether cortisol activates immune cells via IsoLG formation, we performed flow
297 cytometry to analyze IsoLGs present in APCs using a gating strategy shown in **Figure 3A**. We
298 found that urine cortisol levels positively correlated with IsoLG accumulation in classical
299 monocytes, non-classical monocytes, and intermediate monocytes. (**Figure 3B**). In addition, we
300 found that plasma EET8-9, EET11-12, EET14-15 and total EETs negatively correlated with urine
301 cortisol. Whereas urine EET8-9 and EET11-12 did not correlate, EET14-15 and total EETs
302 significantly correlated with baseline urine cortisol (**Figure 3C**). These results suggest that EETs
303 and cortisol play a role in APC ENaC-mediated IsoLG production in SSBP.

304

305 **Aldosterone and renin are not associated with immune cell activation via IsoLGs in SSBP**

306 To determine the role of aldosterone and renin in immune cell activation via IsoLGs in SSBP, we
307 measured APC IsoLGs using flow cytometry, as well as aldosterone, renin, and the aldosterone-
308 renin ratio in plasma. We found no correlation of baseline APC IsoLGs with aldosterone, renin,
309 and aldosterone-renin ratio (**Figure 4A**). Moreover, we did not find any significant correlations
310 between changes in APC IsoLGs and aldosterone, renin, or aldosterone-renin ratio (**Figure 4B**).

311

312 **DISCUSSION:**

313 We recently found that human immune cells express a unique sodium channel composed of ENaCa
314 and ENaC δ , which is not found in the human kidney, and its expression patterns change with
315 blood pressure following salt loading and salt-depletion in SSBP.^{8,15,36} We also previously found
316 that salt-induced expression of ENaC in immune cells is regulated by SGK1¹⁵ and that changes in
317 SGK1 expression in APCs parallel blood pressure changes during salt-loading/depletion in people
318 with SSBP³⁶. Data presented in the current study indicate that the GR, not the MR, signaling via
319 cortisol is responsible for myeloid APC ENaC regulation upstream of SGK1 (**Figure 5**). Our

320 studies show that myeloid APCs do not express the MR but rather express the GR which was
321 associated with expression of SGK1 in these cells. In this study, we also found that cortisol, not
322 aldosterone, is associated with SSBP and immune cell activation via IsoLGs. Implication of the
323 GR-SGK1-ENaC signaling pathway in SSBP underscore the unique pathogenesis of this
324 independent risk factor for CVD and the importance of developing unique immune targeted
325 treatments different from salt-resistant hypertension.

326
327 Previous studies have shown that Blacks have a higher prevalence of SSBP than Whites, yet they
328 have lower plasma levels of aldosterone, enhanced response to amiloride and paradoxical increases
329 in response to salt with higher expression as well as sensitivity of SGK1.^{37,38} Moreover, mice
330 lacking SGK1 are protected against salt-sensitive hypertension induced by a high-fat diet.³⁹
331 We demonstrated previously the essential role of APC SGK1 in SSBP.^{8,15} Whereas the role of
332 SGK1 activation downstream of MR activation by aldosterone has been extensively studied in
333 chronic salt-induced hypertension secondary to renal perturbations,⁴⁰ the mechanism of SGK1
334 activation in the context of acute blood pressure changes according to salt-intake (SSBP) has not
335 been studied. Here we show that myeloid APCs lack MR expression but instead, we demonstrate
336 high levels of GR expression in these cells (**Figure 1**).
337

338 In previous studies, we showed that chronic treatment of salt and aldosterone induces blood
339 pressure elevations secondary to renal tubular remodeling.⁴⁰ However, we found that plasma
340 aldosterone levels do not correlate with SSBP in humans.³⁵ In the current studies, we demonstrate
341 that changes in both plasma and urine cortisol correlate with human SSBP (**Figure 2**). Moreover,
342 cortisol but not aldosterone correlates with immune cell activation via IsoLGs (**Figures 3 and 4**).
343

344 Loss-of-function mutations in *HSD11B2* are strongly associated with SSBP, and cortisol excess
345 often correlates with hypertension⁴¹. Glucocorticoids, mineralocorticoids, and inflammatory
346 factors stimulate the production of SGK1⁴². Although GR, also known as *NR3C1*, is expressed
347 widely in immune cells, its expression is highest in monocytes, as is *SGK1* (**Figure 1D**). Typically,
348 the GR forms a nuclear transcription factor complex to attenuate inflammatory responses⁴³. We
349 found that independent of MR, *NR3C1* gene expression increased in hypertensive patients after
350 treatment with high salt, suggesting an alternative proinflammatory mechanism of high-salt-

351 dependent SGK1 activation by GR. Our research indicates that SGK1 regulates ENaC-dependent
352 sodium entry into APCs, leading to SSBP and inflammatory response through IsoLG formation
353 by the NRPL3 inflammasome and IL-1 β production.⁸

354

355 We also showed that myeloid cell ENaC-induced inflammation and SSBP are regulated
356 independently of the renin-angiotensin-aldosterone system (RAAS).³⁵ Here, we provide further
357 evidence of this, as we observed no correlation between baseline levels of aldosterone, renin, and
358 the aldosterone/renin ratio (ARR) with %IsoLG levels in immune cells (**Figure 4A**). Moreover,
359 the differences in %IsoLG levels between salt loading and depletion did not correlate with any of
360 these measures (**Figure 4B**). These results suggest the regulation of immune cell ENaC in SSBP
361 through the GR pathway rather than the RAAS system.

362

363 It is worth noting that the prevalence of SSBP is higher in women than in men across all ethnicities
364 and increases with age in both genders, raising the question of whether a cortisol-dependent
365 pathway plays a role in sex and age related differences in SSBP.^{44,45} Previous research has
366 indicated that cortisol levels are higher in men who are salt-sensitive compared to those who are
367 salt-resistant⁴⁶. However, to date, there are limited studies that investigate gender differences in
368 cortisol metabolism. One review suggested that loss of estrogen increases the risk for SSBP in
369 postmenopausal women⁴⁵. While the intricate effect of estrogen on SSBP is not well known
370 currently, the increase in SSBP prevalence in menopause can be attributed to age related increase
371 in cortisol alone, as increased cortisol levels are also associated with age and late-stage
372 menopause.^{47,48} It should also be noted that psychosocial stressors affect cortisol metabolism and
373 diurnal response of cortisol levels and linked to poorer health outcomes which may also affect
374 social, racial and gender differences in SSBP.⁴⁹

375

376 An important aspect to consider is the interpretation of plasma cortisol levels, as they reflect the
377 pulsatile nature of the hypothalamus-pituitary-adrenal (HPA) axis. This pulsatile release occurs in
378 approximately 90-minute intervals and peaks in the early morning, which coincides with our
379 plasma sampling period. Conversely, urine cortisol levels are sustained over a longer time period.⁵⁰
380 Indeed, urine cortisol levels are typically considered a more reliable measurement and are
381 frequently used as a diagnostic tool for conditions involving glucocorticoid excess, such as

382 Cushing's syndrome. Collectively, this suggests that urine cortisol would serve as a more reliable
383 diagnostic biomarker for SSBP when compared to plasma cortisol

384

385 Our study has several limitations. First, the limited sample size did not permit us to investigate
386 whether the difference in cortisol excretion in urine could explain the observed race and gender
387 differences in SSBP. Furthermore, the design of our study and the limited availability of the human
388 cells make it difficult to draw direct causal inferences regarding GR-induced SGK1 expression
389 and IsoLG production in APCs. Instead, it allows us to explore the existence of such an association
390 and further mechanistic studies with larger sample sizes are necessary to confirm such differences
391 and causality. Despite these limitations, our single-cell non-supervised evidence with confirmation
392 of bulk RNA studies that myeloid APC do not express the MR, but instead express the GR are
393 highly rigorous. Moreover, to our knowledge, this is the first study to demonstrate that GR, not
394 MR, responds to dynamic changes in dietary salt intake in humans. This novel finding provides a
395 new direction for further research into the role of immune cortisol-GR signaling in SSBP.

396

397 In summary, our results suggest that cortisol signaling contributes to immune cell activation and
398 SSBP rather than aldosterone signaling. These findings indicate a novel glucocorticoid-mediated
399 mechanism for SSBP that may parallel stress-induced hypertension.

400 **Author Contributions:**

401

402 A.K., T.K., and M.S. conceived and designed the research; C.F.A., M.S., J.A.I., A.L.M. and A.P.H.
403 performed the experiments; M.S., K.N., Q.S., M.D., J.A.I., A.L.M., C.L.L., C.N.W., H.K.B.,
404 A.G.M., Z.V., and A.H. analyzed the data; C.F.A., M.D., T.K., and A.K. interpreted the results of
405 the experiments; M.S., Q.S., C.L.L., K.N., A.G.M., A.H.J., H.K.B., M.D., A.L.M., and Z.V.
406 prepared the figures. C.F.A., M.D., and K.N. drafted the manuscript; A.H. and A.K. edited and
407 revised the manuscript; T.A.I, V.K., A.H. and A.K. approved the final version of the manuscript.
408 All authors have reviewed and agreed to the current version of the manuscript.

409

410 **SOURCES OF FUNDING**

411 This study was supported by the National Institutes of Health grants D34HP16299, T32AI007281,
412 T32GM14492, T32HL00773 (CFA), R01HL147818 (AK and TK), T32HL144446 (AP),
413 R03HL155041 (AK), R01HL144941 (AK), Doris Duke CSDA 2021193 (CNW), K23 HL156759
414 (CNW), Burroughs Wellcome Fund 1021480 (CNW), the Vanderbilt CTSA grant UL1TR002243
415 from NCATS/NIH, NIH grants DK059637 and DK020593 to Vanderbilt University Medical
416 Center Hormone Assay and Analytical Services Core, R01HL138519 (AKH), R56AG068026
417 (ERG). The UNCF/Bristol-Myers Squibb E.E. Just Faculty Fund, Career Award at the Scientific
418 Interface (CASI Award) from Burroughs Wellcome Fund (BWF) ID # 1021868.01, BWF Ad-hoc
419 Award, NIH Small Research Pilot Subaward to 5R25HL106365-12 from the National Institutes of
420 Health PRIDE Program, DK020593, Vanderbilt Diabetes and Research Training Center (DRTC)
421 Alzheimer's Disease Pilot & Feasibility Program. CZI Science Diversity Leadership grant number
422 2022- 253529 from the Chan Zuckerberg Initiative DAF, an advised fund of the Silicon Valley
423 Community Foundation (AHJ), AHA career development award 23CDA1053072 (MS).

424

425

426 **REFERENCES**

- 427 1. He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to
428 implementation. *Prog Cardiovasc Dis* 2010;52:363–382. doi:10.1016/j.pcad.2009.12.006.
- 429 2. Strazzullo P, D'Elia L, Kandala N-B, Cappuccio FP. Salt intake, stroke, and cardiovascular
430 disease: meta-analysis of prospective studies. *BMJ* 2009;339:b4567. doi:10.1136/bmj.b4567.
- 431 3. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity
432 and cardiovascular events in patients with essential hypertension. *Lancet Lond Engl*
433 1997;350:1734–1737. doi:10.1016/S0140-6736(97)05189-1.
- 434 4. Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hypertension. *Curr Hypertens Rep*
435 2011;13:55–66. doi:10.1007/s11906-010-0167-6.
- 436 5. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure,
437 and death in normal and hypertensive humans. *Hypertens Dallas Tex* 1979 2001;37:429–
438 432. doi:10.1161/01.hyp.37.2.429.
- 439 6. Iyer RS, Ghosh S, Salomon RG. Levuglandin E2 crosslinks proteins. *Prostaglandins*
440 1989;37:471–480. doi:10.1016/0090-6980(89)90096-8.
- 441 7. Ruggeri Barbaro N, Van Beusecum J, Xiao L, do Carmo L, Pitzer A, Loperena R, et al. Sodium
442 activates human monocytes via the NADPH oxidase and isolevuglandin formation.
443 *Cardiovasc Res* 2021;117:1358–1371. doi:10.1093/cvr/cvaa207.
- 444 8. Pitzer A, Eliovich F, Laffer CL, Ertuglu LA, Sahinoz M, Saleem M, et al. DC ENaC-
445 Dependent Inflammasome Activation Contributes to Salt-Sensitive Hypertension. *Circ Res*
446 2022;131:328–344. doi:10.1161/CIRCRESAHA.122.320818.
- 447 9. Barbaro NR, Foss JD, Kryshtal DO, Tsyba N, Kumaresan S, Xiao L, et al. Dendritic Cell
448 Amiloride-Sensitive Channels Mediate Sodium-Induced Inflammation and Hypertension.
449 *Cell Rep* 2017;21:1009–1020. doi:10.1016/j.celrep.2017.10.002.
- 450 10. Demirci M, Hinton A, Kirabo A. Dendritic cell epithelial sodium channel induced
451 inflammation and salt-sensitive hypertension. *Curr Opin Nephrol Hypertens* 2024;33:145–
452 153. doi:10.1097/MNH.0000000000000963.
- 453 11. Rossier BC, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control
454 of sodium balance: interaction between genetic and environmental factors. *Annu Rev Physiol*
455 2002;64:877–897. doi:10.1146/annurev.physiol.64.082101.143243.
- 456 12. Bubien JK. Epithelial Na⁺ channel (ENaC), hormones, and hypertension. *J Biol Chem*
457 2010;285:23527–23531. doi:10.1074/jbc.R109.025049.
- 458 13. Pratt JH. Central role for ENaC in development of hypertension. *J Am Soc Nephrol JASN*
459 2005;16:3154–3159. doi:10.1681/ASN.2005050460.
- 460 14. Ertuglu LA, Pitzer Mutchler A, Jamison S, Laffer CL, Eliovich F, Saleem M, et al. Eicosanoid-Regulated Myeloid ENaC and Isolevuglandin Formation in Human Salt-
461 Sensitive Hypertension. *Hypertens Dallas Tex* 1979 2023.
462 doi:10.1161/HYPERTENSIONAHA.123.21285.
- 463 15. Van Beusecum JP, Barbaro NR, McDowell Z, Aden LA, Xiao L, Pandey AK, et al. High
464 Salt Activates CD11c⁺ Antigen-Presenting Cells via SGK (Serum Glucocorticoid Kinase) 1
465 to Promote Renal Inflammation and Salt-Sensitive Hypertension. *Hypertens Dallas Tex* 1979
466 2019;74:555–563. doi:10.1161/HYPERTENSIONAHA.119.12761.
- 467 16. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of
468 cortisol excess. *Vasc Health Risk Manag* 2005;1:291–299. doi:10.2147/vhrm.2005.1.4.291.
- 469 17. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. *J Clin Endocrinol*
470 *Metab* 2003;88:2384–2392. doi:10.1210/jc.2003-030138.

472 18. Hunter RW, Ivy JR, Bailey MA. Glucocorticoids and renal Na⁺ transport: implications for
473 hypertension and salt sensitivity. *J Physiol* 2014;592:1731–1744.
474 doi:10.1113/jphysiol.2013.267609.

475 19. Byrd JB, Rothberg AE, Chomic R, Burant CF, Brook RD, Auchus RJ. Serum Cortisol-to-
476 Cortisone Ratio and Blood Pressure in Severe Obesity before and after Weight Loss.
477 *Cardiorenal Med* 2015;6:1–7. doi:10.1159/000438462.

478 20. Nesterov V, Bertog M, Canonica J, Hummler E, Coleman R, Welling PA, et al. Critical role
479 of the mineralocorticoid receptor in aldosterone-dependent and aldosterone-independent
480 regulation of ENaC in the distal nephron. *Am J Physiol-Ren Physiol* 2021;321:F257–F268.
481 doi:10.1152/ajprenal.00139.2021.

482 21. Gomez-Sanchez E, Gomez-Sanchez CE. The Multifaceted Mineralocorticoid Receptor.
483 *Compr Physiol* 2014;4:965–994. doi:10.1002/cphy.c130044.

484 22. Fujita T. Mineralocorticoid Receptors, Salt-Sensitive Hypertension, and Metabolic
485 Syndrome. *Hypertension* 2010;55:813–818.
486 doi:10.1161/HYPERTENSIONAHA.109.149062.

487 23. Itani OA, Liu KZ, Cornish KL, Campbell JR, Thomas CP. Glucocorticoids stimulate human
488 sgk1 gene expression by activation of a GRE in its 5'-flanking region. *Am J Physiol-
489 Endocrinol Metab* 2002;283:E971–E979. doi:10.1152/ajpendo.00021.2002.

490 24. Verouti S, Hummler E, Vanderriele P-E. Role of glucocorticoid receptor mutations in
491 hypertension and adrenal gland hyperplasia. *Pflugers Arch* 2022;474:829–840.
492 doi:10.1007/s00424-022-02715-6.

493 25. Biddie SC, Hager GL. Glucocorticoid receptor dynamics and gene regulation. *Stress*
494 2009;12:193–205. doi:10.1080/10253890802506409.

495 26. Laffer CL, Laniado-Schwartzman M, Wang M-H, Nasjletti A, Eliovich F. 20-HETE and
496 Furosemide-Induced Natriuresis in Salt-Sensitive Essential Hypertension. *Hypertension*
497 2003;41:703–708. doi:10.1161/01.HYP.0000051888.91497.47.

498 27. Eliovich F, Milne GL, Brown NJ, Laniado-Schwartzman M, Laffer CL. Two Pools of
499 Epoxyeicosatrienoic Acids in Humans. *Hypertension* 2018;71:346–355.
500 doi:10.1161/HYPERTENSIONAHA.117.10392.

501 28. Heaton H, Talman AM, Knights A, Imaz M, Gaffney DJ, Durbin R, et al. Souporcell: robust
502 clustering of single-cell RNA-seq data by genotype without reference genotypes. *Nat
503 Methods* 2020;17:615–620. doi:10.1038/s41592-020-0820-1.

504 29. Franzén O, Gan L-M, Björkegren JLM. PanglaoDB: a web server for exploration of mouse
505 and human single-cell RNA sequencing data. *Database J Biol Databases Curation*
506 2019;2019:baz046. doi:10.1093/database/baz046.

507 30. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic
508 data across different conditions, technologies, and species. *Nat Biotechnol* 2018;36:411–420.
509 doi:10.1038/nbt.4096.

510 31. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
511 expression analysis of digital gene expression data. *Bioinforma Oxf Engl* 2010;26:139–140.
512 doi:10.1093/bioinformatics/btp616.

513 32. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with
514 revamped UIs and APIs. *Nucleic Acids Res* 2019;47:W199–W205. doi:10.1093/nar/gkz401.

515 33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene
516 set enrichment analysis: a knowledge-based approach for interpreting genome-wide

517 expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–15550.
518 doi:10.1073/pnas.0506580102.

519 34. Ruggeri Barbaro N, Van Beusecum J, Xiao L, do Carmo L, Pitzer A, Loperena R, et al.
520 Sodium activates human monocytes via the NADPH oxidase and isolevuglandin formation.
521 *Cardiovasc Res* 2021;117:1358–1371. doi:10.1093/cvr/cvaa207.

522 35. Ertuglu LA, Pitzer Mutchler A, Eliovich F, Laffer CL, Sheng Q, Wanjalla CN, et al.
523 Regulation of human salt-sensitivity hypertension by myeloid cell renin-angiotensin-
524 aldosterone system. *Front Physiol* 2023;14:1208270. doi:10.3389/fphys.2023.1208270.

525 36. Ertuglu LA, Pitzer Mutchler A, Jamison S, Laffer CL, Eliovich F, Saleem M, et al.
526 Eicosanoid-Regulated Myeloid ENaC and Isolevuglandin Formation in Human Salt-
527 Sensitive Hypertension. *Hypertens Dallas Tex* 1979 2024;81:516–529.
528 doi:10.1161/HYPERTENSIONAHA.123.21285.

529 37. Lang F, Böhmer C, Palmada M, Seeböhm G, Strutz-Seeböhm N, Vallon V.
530 (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase
531 isoforms. *Physiol Rev* 2006;86:1151–1178. doi:10.1152/physrev.00050.2005.

532 38. Eliovich F, Kirabo A, Laffer CL. Salt Sensitivity of Blood Pressure in Black People: The
533 Need to Sort Out Ancestry Versus Epigenetic Versus Social Determinants of Its Causation.
534 *Hypertension* 2024;81:456–467. doi:10.1161/HYPERTENSIONAHA.123.17951.

535 39. Huang DY, Boini KM, Osswald H, Friedrich B, Artunc F, Ullrich S, et al. Resistance of mice
536 lacking the serum- and glucocorticoid-inducible kinase SGK1 against salt-sensitive
537 hypertension induced by a high-fat diet. *Am J Physiol Renal Physiol* 2006;291:F1264–1273.
538 doi:10.1152/ajprenal.00299.2005.

539 40. Mutchler SM, Hasan M, Murphy CP, Baty CJ, Boyd-Shiawski C, Kirabo A, et al. Dietary
540 sodium alters aldosterone's effect on renal sodium transporter expression and distal
541 convoluted tubule remodelling. *J Physiol* 2024;602:967–987. doi:10.1113/JP284041.

542 41. Williams TA, Mulatero P, Filigheddu F, Troffa C, Milan A, Argiolas G, et al. Role of
543 HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides.
544 *Kidney Int* 2005;67:631–637. doi:10.1111/j.1523-1755.2005.67119.x.

545 42. Lu R, Zhang Y, Zhao H, Guo R, Jiang Z, Guo R. SGK1, a Critical Regulator of Immune
546 Modulation and Fibrosis and a Potential Therapeutic Target in Chronic Graft-Versus-Host
547 Disease. *Front Immunol* 2022;13.

548 43. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress,
549 glucocorticoid receptor resistance, inflammation, and disease risk. *Proc Natl Acad Sci U S A*
550 2012;109:5995–5999. doi:10.1073/pnas.1118355109.

551 44. Masenga SK, Kirabo A. Hypertensive heart disease: risk factors, complications and
552 mechanisms. *Front Cardiovasc Med* 2023;10.

553 45. Barris CT, Faulkner JL, Belin de Chantemèle EJ. Salt Sensitivity of Blood Pressure in
554 Women. *Hypertension* 2023;80:268–278. doi:10.1161/HYPERTENSIONAHA.122.17952.

555 46. Weber C. Salt-sensitive men show reduced heart rate variability, lower norepinephrine and
556 enhanced cortisol during mental stress. *J Hum Hypertens* 2008.

557 47. Woods NF, Carr MC, Tao EY, Taylor HJ, Mitchell ES. Increased urinary cortisol levels
558 during the menopause transition. *Menopause* 2006;13:212.
559 doi:10.1097/gme.0000198490.57242.2e.

560 48. Larsson CA, Gullberg B, Råstam L, Lindblad U. Salivary cortisol differs with age and sex
561 and shows inverse associations with WHR in Swedish women: a cross-sectional study. *BMC
562 Endocr Disord* 2009;9:16. doi:10.1186/1472-6823-9-16.

563 49. Allen JO, Watkins DC, Chatters L, Geronimus AT, Johnson-Lawrence V. Cortisol and
564 Racial Health Disparities Affecting Black Men in Later Life: Evidence From MIDUS II. *Am
565 J Mens Health* 2019;13:1557988319870969. doi:10.1177/1557988319870969.

566 50. Jung C, Greco S, Nguyen HH, Ho JT, Lewis JG, Torpy DJ, et al. Plasma, salivary and
567 urinary cortisol levels following physiological and stress doses of hydrocortisone in normal
568 volunteers. *BMC Endocr Disord* 2014;14:91. doi:10.1186/1472-6823-14-91.

569

570 **TABLES**

571 **Table 1. Demographic and clinical characteristics of the participants used in Figure 1D**
572 **(Cohort 2) along with those assessed for SSBP (Cohort 1).**

Characteristics of Cohort 1 ^a	All (n=25)		
Study Days	Baseline	Salt Loading	Salt Depletion
Age (years)	53.2±1.6		
Female, n (%)	14 (51.8)		
White race, n (%)	18 (72)		
BMI (kg/m ²)	32.5±1.7		
SBP (mm Hg)	139.82 ± 2.9	142.35±2.6	132.9±2.6
DBP (mm Hg)	85.9±1.9	85.1±2.1	85.7±2.2
MAP (mm Hg)	105.07±1.8	105.52±1.9	103.7±1.8
Serum creatinine (mg/dL)	0.85 ±0.02	0.81 ±0.02	0.97 ±0.03
Urinary Na ⁺ excretion (mmol/day)	149.0±11.8	354.3±21.6	71.4±10.6
Urinary K ⁺ excretion (mmol/day)	52.2±4.0	66.2±4.5	40.73±2.4
Urinary creatinine excretion (mg/day)	1370±96	1331±89	1338±82
PRC (ng/L)	6.86±1.35	5.3±0.9	19.5±4.2
Aldosterone (ng/dL)	10.02±1.3	9.14±1.06	16.3±1.46
ARR	26.3±5.5	26.5±4.4	21.4±4.3
Characteristics of Cohort 2 ^b	(n=11)		
Age, y	34.7±11.8		
Female, n (%)	11 (100)		
White race, n (%)	10 (91)		
SBP (mm Hg)	110.9±16.7		
DBP (mm Hg)	69.0±6.8		
HTN, %	9		
BMI (kg/m ²)	28.6±17.5		

573 ^aData for continuous variables are presented as mean±SEM









574 ^bData for continuous variables are presented as mean±SD

575

576 BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN,
577 hypertension; MAP, mean arterial pressure; ARR, aldosterone/renin ratio.

578


579 **FIGURES AND LEGENDS**



581 **Figure 1: Salt-sensitivity of Blood Pressure Phenotyping and NR3C1 and SGK1 gene**
582 **expression. A)** Diagram of the 72-hour inpatient salt-loading (SL) and salt-depletion (SD) protocol
583 with changes in urinary sodium excretion (UNa+V) and systolic blood pressure (Δ SBP). **B)** Dot
584 plot and Uniform Manifold Approximation and Projection (UMAP) representations of relevant
585 gene expression in different immune cell type clusters after CITE-Seq analysis. Patients with the
586 highest salt-sensitivity index were indicated as salt sensitive while those with the lowest were
587 indicated as salt resistant. Days 1, 2, and 3 represent baseline, salt loading, and salt depletion,
588 respectively. **C)** Correlation between changes in gene expression of *SGK1* and *NR3C1* from SL to
589 SD. **D)** Violin plots comparing gene transcript counts via bulk RNA-Seq after normal-salt and
590 high-salt treatments (n=11). Adjusted p values for each pairwise comparison are shown using false
591 discovery rate (FDR < 0.05). NR3C1 indicates Nuclear Receptor Subfamily 3, Group C, Member
592 1; NR3C2, Nuclear Receptor Subfamily 3, Group C, Member 2; SR, salt-resistant; SS, salt-
593 sensitive.

594

595




596

597 **Figure 2: Glucocorticoid metabolome influences hemodynamics**

598 (A-D) Scatter plots demonstrating the correlations between blood pressure and changes in (A)
599 urine cortisol, (B) plasma cortisol, (C) urine cortisone, and (D) plasma cortisone from mass-
600 spectroscopy analysis. Each metabolite is measured for changes in systolic blood pressure (ΔSBP),
601 diastolic blood pressure (ΔDBP), mean arterial pressure (ΔMAP), and pulse pressure (ΔPP). SL-
602 SD represents difference between the values of salt loading and salt depletion, while SL-BL
603 represents the difference between the values of salt loading and baseline. Trend lines and
604 confidence intervals were estimated using linear regression. The significance and r values were
605 computed using Pearson's correlation test. Normality of distribution was assessed using Shapiro-
606 Wilk test.

607




608

609 **Figure 3: Urine cortisol is positively correlated with IsoLG percentage and negatively**
 610 **correlated with plasma EETs.**

611 (A) Gating strategy to identify IsoLG-adducts in dendritic cells (DCs) and classical, intermediate,
 612 and non-classical monocytes. (B) Scatter plots demonstrating the correlations between baseline
 613 percent of IsoLGs and baseline urine cortisol in classical monocytes, non-classical monocytes,
 614 intermediate monocytes, and dendritic cells. (C) Correlations of baseline plasma and urine EETs
 615 with baseline urine cortisol in classical monocytes, non-classical monocytes, intermediate
 616 monocytes, and dendritic cells. Trend lines and confidence intervals were estimated with linear
 617 regression and the significance and r value were computed using Spearman's rank correlation.

618




619

620 **Figure 4: Correlations of IsoLGs with aldosterone and renin.**

621 (A) Scatter plots demonstrating the correlations between baseline percent of IsoLGs and baseline
622 aldosterone, renin, and aldosterone-renin ratio in classical monocytes, non-classical monocytes,
623 intermediate monocytes, and dendritic cells. (B) Correlations of changes in percent of IsoLGs with
624 changes in plasma aldosterone, renin, and aldosterone-renin ratio in classical monocytes, non-
625 classical monocytes, intermediate monocytes, and dendritic cells. All the delta (Δ) variables were
626 calculated as the difference between values on salt loading and salt depletion days (SL-SD). Trend
627 lines and confidence intervals were estimated with linear regression. R value and the significance
628 were computed using Spearman's rank correlation.

629



630

631 **Figure 5: Proposed mechanism for the role of cortisol in SSBP.**

632 The release of cortisol from the adrenal gland is a direct response to adrenocorticotropic hormone
633 (ACTH) production by the anterior pituitary gland, which is controlled by the hypothalamus.
634 Cortisol activates glucocorticoid receptor, likely inducing *SGK1* expression for the regulation of
635 epithelial sodium channel (ENaC) in monocytes. High levels of extracellular sodium enter the
636 monocytes via ENaC to cause an influx of calcium ions through the $\text{Na}^+/\text{Ca}^{2+}$ exchanger. Calcium
637 induces NADPH oxidase activation, producing reactive oxygen species (ROS) and IsoLGs.
638 Subsequent T-cell activation and renal damage are events that are indicative of salt-sensitive
639 hypertension.

640 **Novelty and Relevance**

641 **What Is New?**

642 • Although salt sensitivity is a major risk factor for cardiovascular morbidity and mortality,
643 the mechanisms underlying the salt sensitivity of blood pressure (SSBP) are poorly
644 understood.

645 • High salt modifies glucocorticoid-receptor expression in antigen-presenting cells (APCs),
646 suggesting a critical role of glucocorticoids in SSBP.

647 • Elevated glucocorticoid receptor (GR) expression compared to mineralocorticoid receptor
648 (MR) expression in APCs provides evidence for a GR-dependent pathway to SSBP.
649 Isolevuglandins (IsoLGs) increased in APCs *in vitro* after hydrocortisone treatment
650 compared to aldosterone treatment, indicating that cortisol was the predominant driver of
651 IsoLG production in these cells.

652 • Our studies suggest a mechanism for *SGK1* expression through GR activation by cortisol
653 that differs from the currently accepted mechanism for SSBP pathogenesis.

654 **What Is Relevant?**

655 • Although aldosterone has been used to study SSBP, there has been no consideration of
656 cortisol as a major driver of the condition.

657 • Understanding alternative inflammatory pathways that affect SSBP may provide insights
658 into the mechanism of SSBP and suggest a range of therapeutic targets.

659 • Our studies may provide a practical approach to understanding and treating salt-sensitive
660 hypertension.

661 **Clinical/Pathophysiological Implications?**

662 • Our findings firmly support a GR-dependent signaling pathway for activating SSBP via
663 *SGK1* expression. A cortisol-driven mechanism could provide a practical approach for
664 targeted treatments for salt-sensitive hypertension. Moreover, it could pave the way for a
665 diagnostic approach.